Immunovant, Inc.

Developing FcRn inhibition for multiple autoimmune diseases, with development now focused on IMVT-1402.

Back to company catalog

Autoimmune disease · FcRn-targeting monoclonal antibody · Registrational Phase 3

Compare report options